메뉴 건너뛰기




Volumn 18, Issue 6, 2016, Pages 896-903

The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C

Author keywords

directly acting antivirals; hepatitis C; liver transplantation

Indexed keywords

4 ACETANISIDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN; DACLATASVIR; EVEROLIMUS; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; INTERFERON; MYCOPHENOLATE MOFETIL; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; VIRUS RNA; AMINOTRANSFERASE; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

EID: 85005817963     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12606     Document Type: Article
Times cited : (22)

References (33)
  • 2
    • 0035748137 scopus 로고    scopus 로고
    • Hepatitis C and hepatocellular carcinoma
    • Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options Oncol. 2001;2:473–483.
    • (2001) Curr Treat Options Oncol , vol.2 , pp. 473-483
    • Yao, F.1    Terrault, N.2
  • 3
    • 84872119847 scopus 로고    scopus 로고
    • Update in liver transplantation
    • Alqahtani SA. Update in liver transplantation. Discov Med. 2012;14:133–141.
    • (2012) Discov Med , vol.14 , pp. 133-141
    • Alqahtani, S.A.1
  • 5
    • 46349089961 scopus 로고    scopus 로고
    • Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
    • Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–287.
    • (2008) J Hepatol , vol.49 , pp. 274-287
    • Berenguer, M.1
  • 6
    • 33745343818 scopus 로고    scopus 로고
    • Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis
    • Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–1599.
    • (2006) Am J Transplant , vol.6 , pp. 1586-1599
    • Wang, C.S.1    Ko, H.H.2    Yoshida, E.M.3    Marra, C.A.4    Richardson, K.5
  • 7
    • 84919686294 scopus 로고    scopus 로고
    • Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals
    • Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. Liver Int. 2015;35(Suppl 1):44–50.
    • (2015) Liver Int , vol.35 , pp. 44-50
    • Coilly, A.1    Roche, B.2    Duclos-Vallée, J.C.3    Samuel, D.4
  • 8
    • 84899008211 scopus 로고    scopus 로고
    • Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity
    • Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity.” Am J Transplant. 2014;14:994–1002.
    • (2014) Am J Transplant , vol.14 , pp. 994-1002
    • Gane, E.J.1    Agarwal, K.2
  • 10
    • 84938739029 scopus 로고    scopus 로고
    • Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting
    • Beinhardt S, Peck-Radosavljevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Transpl Int. 2015;28:1011–1024.
    • (2015) Transpl Int , vol.28 , pp. 1011-1024
    • Beinhardt, S.1    Peck-Radosavljevic, M.2    Hofer, H.3    Ferenci, P.4
  • 11
    • 84911409020 scopus 로고    scopus 로고
    • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
    • Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
    • (2014) Lancet , vol.384 , pp. 1756-1765
    • Lawitz, E.1    Sulkowski, M.S.2    Ghalib, R.3
  • 12
    • 84892619580 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
    • Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
    • (2014) N Engl J Med , vol.370 , pp. 211-221
    • Sulkowski, M.S.1    Gardiner, D.F.2    Rodriguez-Torres, M.3
  • 13
    • 84930034351 scopus 로고    scopus 로고
    • Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients
    • Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823–830.
    • (2015) Liver Transpl , vol.21 , pp. 823-830
    • Gutierrez, J.A.1    Carrion, A.F.2    Avalos, D.3
  • 14
    • 84945442148 scopus 로고    scopus 로고
    • Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients
    • Saab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35:2442–2447.
    • (2015) Liver Int , vol.35 , pp. 2442-2447
    • Saab, S.1    Greenberg, A.2    Li, E.3
  • 15
    • 84920941109 scopus 로고    scopus 로고
    • Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late
    • Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923–927.
    • (2014) Dig Liver Dis , vol.46 , pp. 923-927
    • Pellicelli, A.M.1    Montalbano, M.2    Lionetti, R.3
  • 16
    • 84878475234 scopus 로고    scopus 로고
    • Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C
    • Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601–1605.
    • (2013) Am J Transplant , vol.13 , pp. 1601-1605
    • Fontana, R.J.1    Hughes, E.A.2    Bifano, M.3
  • 17
    • 84961886745 scopus 로고    scopus 로고
    • Direct acting antiviral therapy after liver transplantation
    • Kwo PY. Direct acting antiviral therapy after liver transplantation. Curr Opin Gastroenterol. 2016;32:152–158.
    • (2016) Curr Opin Gastroenterol , vol.32 , pp. 152-158
    • Kwo, P.Y.1
  • 18
    • 68249119265 scopus 로고    scopus 로고
    • Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity
    • Stockmann M, Lock JF, Riecke B, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250:119–125.
    • (2009) Ann Surg , vol.250 , pp. 119-125
    • Stockmann, M.1    Lock, J.F.2    Riecke, B.3
  • 19
    • 84925033610 scopus 로고    scopus 로고
    • Reliable assessment of liver function using LiMAx
    • Jara M, Bednarsch J, Valle E, et al. Reliable assessment of liver function using LiMAx. J Surg Res. 2015;93:184–189.
    • (2015) J Surg Res , vol.93 , pp. 184-189
    • Jara, M.1    Bednarsch, J.2    Valle, E.3
  • 21
    • 84922318694 scopus 로고    scopus 로고
    • Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
    • Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–16.
    • (2015) Antiviral Res , vol.116 , pp. 10-16
    • Sarrazin, C.1    Lathouwers, E.2    Peeters, M.3
  • 22
    • 84901217985 scopus 로고    scopus 로고
    • Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial
    • Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669–1679.
    • (2014) Gastroenterology , vol.146 , pp. 1669-1679
    • Forns, X.1    Lawitz, E.2    Zeuzem, S.3
  • 23
    • 33847007641 scopus 로고    scopus 로고
    • Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy)
    • Bahra M, Neumann UP, Jacob D, et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation. 2007;83:351–353.
    • (2007) Transplantation , vol.83 , pp. 351-353
    • Bahra, M.1    Neumann, U.P.2    Jacob, D.3
  • 24
    • 84983573872 scopus 로고    scopus 로고
    • Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation
    • Kawaoka T, Takahashi S, Kawakami Y, et al. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. Hepatol Res. 2015;45:1047–1054.
    • (2015) Hepatol Res , vol.45 , pp. 1047-1054
    • Kawaoka, T.1    Takahashi, S.2    Kawakami, Y.3
  • 25
    • 84871272411 scopus 로고    scopus 로고
    • Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients
    • Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transpl Int. 2013;26:42–49.
    • (2013) Transpl Int , vol.26 , pp. 42-49
    • Tanaka, T.1    Selzner, N.2    Therapondos, G.3    Renner, E.L.4    Lilly, L.B.5
  • 26
    • 0242708704 scopus 로고    scopus 로고
    • Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection
    • Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003;9:1159–1165.
    • (2003) Liver Transpl , vol.9 , pp. 1159-1165
    • Kugelmas, M.1    Osgood, M.J.2    Trotter, J.F.3
  • 27
    • 0026662551 scopus 로고
    • Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
    • Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753–761.
    • (1992) Drug Metab Dispos , vol.20 , pp. 753-761
    • Sattler, M.1    Guengerich, F.P.2    Yun, C.H.3    Christians, U.4    Sewing, K.F.5
  • 29
    • 79958708777 scopus 로고    scopus 로고
    • Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week
    • Lock JF, Malinowski M, Schwabauer E, et al. Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week. Clin Transplant. 2011;25:436–443.
    • (2011) Clin Transplant , vol.25 , pp. 436-443
    • Lock, J.F.1    Malinowski, M.2    Schwabauer, E.3
  • 30
    • 84930578857 scopus 로고    scopus 로고
    • Drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients
    • Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients. Ann Pharmacother. 2015;49:674–687.
    • (2015) Ann Pharmacother , vol.49 , pp. 674-687
    • Burgess, S.1    Partovi, N.2    Yoshida, E.M.3    Erb, S.R.4    Azalgara, V.M.5    Hussaini, T.6
  • 31
    • 77956328248 scopus 로고    scopus 로고
    • How to define initial poor graft function after liver transplantation? A new functional definition by the LiMAx test
    • Stockmann M, Lock JF, Malinowski M, et al. How to define initial poor graft function after liver transplantation? A new functional definition by the LiMAx test. Transpl Int. 2010;23:1023–1032.
    • (2010) Transpl Int , vol.23 , pp. 1023-1032
    • Stockmann, M.1    Lock, J.F.2    Malinowski, M.3
  • 32
    • 84925033610 scopus 로고    scopus 로고
    • Reliable assessment of liver function using LiMAx
    • Jara M, Bednarsch J, Valle E, et al. Reliable assessment of liver function using LiMAx. J Surg Res. 2015;193:184–189.
    • (2015) J Surg Res , vol.193 , pp. 184-189
    • Jara, M.1    Bednarsch, J.2    Valle, E.3
  • 33
    • 84919587847 scopus 로고    scopus 로고
    • Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test
    • Malinowski M, Jara M, Lüttgert K, et al. Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test. Dig Dis Sci. 2014;59:2983–2991.
    • (2014) Dig Dis Sci , vol.59 , pp. 2983-2991
    • Malinowski, M.1    Jara, M.2    Lüttgert, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.